Lonza is to set up a virtual tenancy at Stevenage Bioscience Catalyst (SBC). Through this collaboration, Lonza’s scientific experts will establish a regular presence at SBC working with the Business Development team, joining a vibrant community for biotech growth and development.
Sarah Holland, Global Head of Licensing at Lonza commented: “Supporting innovation is a key focus for Lonza. Working closely with SBC gives us the opportunity to build strong relationships with other residents at the BioCatalyst. Interacting with other companies in this highly networked and innovative environment, in one of the UK’s leading hotspots for life-science innovation, will help fast-track opportunities for collaboration and set programs up early for industrial-quality manufacturing platforms."
Dr Sally Ann Forsyth, CEO of SBC, commented: "This is a great opportunity to create synergies between a large organisation, such as Lonza and our entrepreneurial environment. Our ultimate aim is to close the gap between translational innovative science and medical advancement; through this new initiative, we will be able to support further collaboration and accelerate that process."
Lonza is an integrated solutions provider that creates value along the Healthcare Continuum®. Through our Pharma Biotech & Nutrition segment and our Specialty Ingredients segment businesses, we harness science and technology to serve markets along this continuum. We focus on creating a healthy environment, promoting a healthier lifestyle and preventing illness through consumers' preventive healthcare, as well as improving patient healthcare by supporting our customers to deliver innovative medicines that help treat or even cure severe diseases.
Patients and consumers benefit from our ability to transfer our pharma know-how to the healthcare, hygiene and fast-moving consumer goods environment and to the preservation and protection of the world where we live.
Founded in 1897 in the Swiss Alps, Lonza today is a well-respected global company with more than 100 sites and offices and approximately 15,500 full-time employees worldwide at the end of 2018. The company generated sales of CHF 5.5 billion in 2018 with a CORE EBITDA of CHF 1.5 billion. Further information can be found at www.lonza.com.
About Stevenage Bioscience Catalyst
Our aim is to build a globally recognised cluster for therapeutics and enabling technologies that provides support for translation and commercialisation, both within the UK and internationally, to help deliver innovative new medicines to patients.